A novel modular antigen delivery system for immuno targeting of human 6-sulfo LacNAc-positive blood dendritic cells (slanDCs)

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Bippes, Claudia C ^a   Feldmann, Anja ^a   Stamova, Slava ^a   Cartellieri, Marc ^a   Schwarzer, Adrian ^a   Wehner, Rebekka ^a   Schmitz, Marc ^a,b   Rieber, E Peter ^a   Zhao, Senming ^a,c   Schäkel, Knut ^a   Temme, Achim ^a   Hal Scofield, R ^d   Kurien, Biji T ^d   Bartsch, Holger ^a   Bachmann, Michael ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^c HEBEI MEDICAL UNIVERSITY   (China)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TETANUS TOXIN; 6 SULFO LACNAC; 6-SULFO-LACNAC; AMINOSUGAR; ANTIGEN; MEMBRANE PROTEIN; P SELECTIN LIGAND PROTEIN; P-SELECTIN LIGAND PROTEIN; VACCINE;

6 SULFO LACNAC POSITIVE BLOOD DENDRITIC CELL; ANTIGEN BINDING; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG STRUCTURE; DRUG TARGETING; EPITOPE MAPPING; HUMAN; HUMAN CELL; MEMORY T LYMPHOCYTE; PEPTIDE MAPPING; TETANUS; ANTIGEN PRESENTATION; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; T LYMPHOCYTE;

AMINO SUGARS; ANTIGEN PRESENTATION; ANTIGENS; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTES; VACCINES;

EID: 79251603274     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016315     Document Type: Article

References (39)

1. Di Noia JM, Neuberger MS (2007) Molecular mechanisms of antibody somatic hypermutation. Annual Rev Biochem 76: 1-22.
2. Rajewsky K (1996) Clonal selection and learning in the antibody system. Nature 381: 751-758.
3. Stavnezer J (2000) Molecular processes that regulate class switching. Curr Top Microbiol Immunol 245: 127-168.
4. Kinoshita K, Honjo T (2001) Linking class-switch recombination with somatic hypermutation. Nat Rev Mol Cell Biol 2: 493-503.
5. Manis JP, Tian M, Alt FW (2002) Mechanism and control of class-switch recombination. Trends Immunol 23: 31-39.
6. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, et al. (1999) Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 25: 18470-18476.
7. Bransteitter R, Pham P, Scharff MD, Goodman MF (2002) Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc Natl Acad Sci U S A 100: 4102-4107.
8. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136.
9. Schäkel K, Mayer E, Federle C, Schmitz M, Riethmüller G, et al. (1998) A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol 28: 4084-4093.
10. Schäkel K, Poppe C, Mayer E, Federle C, Riethmüller G, et al. (1999) M-DC8+ leukocytes-a novel human dendritic cell population. Pathobiology 67: 287-290.
11. Schäkel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, et al. (2002) 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 17: 289-301.
12. Schäkel K, von Kietzell M, Hänsel A, Ebling A, et al. (2006) Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity 24: 767-777.
13. Schmitz M, Zhao S, Deuse Y, Schäkel K, Wehner R, et al. (2005) Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J Immunol 174: 4127-4134.
14. Carmo-Fonseca M, Pfeifer K, Schröder HC, Vaz MF, Fonseca JE, et al. (1989) Identification of La ribonucleoproteins as a component of interchromatin granules. Exp Cell Res 185: 73-85.
15. Moll H (2003) Dendritic cells and host resistance to infection. Cell Microbiol 5: 493-500.
16. Sousa CRE, Sher A, Kaye P (1999) The role of dendritic cells in the induction and regulation of immunity to microbial infection. Curr Opin Immunol 11: 392-399.
17. Wilson NS, Villadangos JA (2005) Regulation of antigen presentation and crosspresentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol 86: 241-305.
18. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5: 296-306.
19. Proudfoot O, Apostolopoulos V, Pietersz GA (2007) Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. Mol Pharm 4: 58-72.
20. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, et al. (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196: 1627-1638.
21. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, et al. (2004) In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199: 815-824.
22. Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21: 685-711.
23. Charalambous A, Oks M, Nchinda G, Yamazaki S, Steinman RM (2006) Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin. J Immunol 177: 8410-8421.
24. Bozzacco L, Trumpfheller C, Siegal FP, Mehandru S, Markowitz M, et al. (2007) DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A 104: 1289-1294.
25. Do Y, Park CG, Kang YS, Park SH, Lynch RM, et al. (2008) Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC- 205/CD205-positive mouse dendritic cells. Eur J Immunol 38: 20-29.
26. Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, et al. (2008) Targeting the nuclear antigen 1 of Epstein Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 112: 1231-1239.
27. Mukhopadhaya A, Hanafusa T, Jarchum I, Chen YG, Iwai Y, et al. (2008) Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc Natl Acad Sci U S A 105: 6374-6379.
28. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, et al. (2000) The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 151: 673-684.
29. Bruder D, Westendorf AM, Hansen W, Prettin S, Gruber AD, et al. (2005) On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes 54: 3395-3401.
30. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, et al. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194: 769-779.
31. Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK, Nussenzweig MC (2004) Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 20: 695-705.
32. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, et al. (2007) Differential antigen processing by dendritic cell subsets in vivo. Science 31: 107-111.
33. Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, et al. (2010) Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood [Epub ahead of print].
34. Maugeri N, Rovere-Querini P, Evangelista V, Covino C, Capobianco A, et al. (2009) Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine, P-selectin, and β2 integrin-dependent cell clearance program. Blood 21: 5254-5265.
35. Malik S, Bruner GR, Williams-Weese C, Feo L, Scofield RH, et al. (2007) Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients. Lupus 16: 863-866.
36. Gaither KK, Fox OF, Yamagata H, Mamula MJ, et al. (1987) Implications of anti-Ro/Sjögren's syndrome A antigen autoantibody in normal sera for autoimmunity. J Clin Invest 79: 841-846.
37. Wang Z, Raifu M, Howard M, Smith L, Hansen D, et al. (2000) Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3′ to 5′ exonuclease activity. J Immunol Methods 13: 167-177.
38. Morgenroth A, Cartellieri M, Schmitz M, Günes S, Weigle B, et al. (2007) Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 67: 1121-1131.
39. Mannering SI, Morris JS, Jensen KP, Purcell AW, Honeyman MC, et al. (2003) A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. J Immunol Methods 283: 173-183.